Cargando…

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

INTRODUCTION: BAY 81‐8973 (Kovaltry(®)) is a full‐length, unmodified recombinant human factor VIII approved in China for prophylaxis and on‐demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically led to this population being undertreated. This s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Renchi, Sun, Jing, Zhao, Yongqiang, Wang, Xuefeng, Wu, Depei, Tseneklidou‐Stoeter, Despina, Wu, Junde, Church, Nikki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850381/ https://www.ncbi.nlm.nih.gov/pubmed/30993836 http://dx.doi.org/10.1111/hae.13751

Ejemplares similares

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS
por: Santoro, Cristina, et al.
Publicado: (2022)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
por: Lalezari, Shadan, et al.
Publicado: (2019)

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
por: Teare, John M, et al.
Publicado: (2019)

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Leopold Sacher-Masoch
por: Michel, Bernard 1935-
Publicado: (1992)

Mr. Leopold Burroughs
Publicado: (1910)

Leopold's Description of the Placenta
por: Barbour, A. H. F.
Publicado: (1898)

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis
por: O’Hara, Jamie, et al.
Publicado: (2021)

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting
por: Chen, Rong, et al.
Publicado: (2022)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

On the Cervix and the Attitude of the Fœtus in Leopold's Sections—'Uterus and Child'
por: Barbour, A. H. F.
Publicado: (1898)

Heritage of Leopold Auerbach in the field of morphology of nervous system
por: Wincewicz, Andrzej, et al.
Publicado: (2021)

Molecular genetic investigations on Austria's patron saint Leopold III
por: Bauer, Christiane Maria, et al.
Publicado: (2013)

Great Achievements under Suffering: V. Leopold, Duke of Albany
Publicado: (1894)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention
por: Mokhtar, Fadzlin Mohd, et al.
Publicado: (2021)

Léopold Sédar Senghor; une étude de Armand Guibert. Avec un choix de poémes [et] une chronologie bibliographique: Léopold Sédar Senghor et son temps.
por: Senghor, Léopold Sédar, 1906-2001
Publicado: (1969)

Exploring Research Frontiers in Contemporary Statistics and Econometrics: A Festschrift for Léopold Simar
por: Keilegom, Ingrid, et al.
Publicado: (2012)

Leopold Auerbach’s heritage in the field of morphology and embryology with special emphasis on gametogenesis of invertebrates
por: Wincewicz, Andrzej, et al.
Publicado: (2020)

A new paradigm for personalized prophylaxis for patients with severe haemophilia A
por: Delavenne, Xavier, et al.
Publicado: (2020)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
por: Cruz, Maria Sol, et al.
Publicado: (2021)

Histoire populaire du règne de Léopold 1er roi des Belges
por: Hymans, Louis Salomon, 1829-1884
Publicado: (1865)

Recent developments in general relativity: Festschrift Infeld (Leopold) on his 60th birthday
por: Bažański, S, et al.
Publicado: (1962)

Environmental impact assessment of Gonabad municipal waste landfill site using Leopold Matrix
por: Sajjadi, Seyed Ali, et al.
Publicado: (2017)

Streptococcus Species Abundance in the Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort
por: Sayols-Baixeras, Sergi, et al.
Publicado: (2023)

Efficacy and Safety Analysis of Combination Therapy Consisting of Intravenous Immunoglobulin and Corticosteroids versus Respective Monotherapies in the Treatment of Relapsed ITP in Adults
por: Fang, Lijun, et al.
Publicado: (2023)

Effect of nursing intervention program using abdominal palpation of Leopold’s maneuvers on maternal-fetal attachment
por: Nishikawa, Miyuki, et al.
Publicado: (2013)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Cannot write session to /tmp/vufind_sessions/sess_pist6cj5db0c0j06v43po0sqr2